alpha-Adrenoceptor subtypes in isolated corporal tissue from patients undergoing gender re-assignment

The role of alpha(1)-adrenoceptors in human corpus cavernosum remains partially understood. Prior research has shown that these receptors regulate smooth muscle contraction in various tissues. However, the specific subtype distribution in cavernosal tissue has not been fully characterized. Existing studies suggest multiple alpha(1) subtypes exist, but their relative affinities in this tissue are unclear. This gap motivated the need for subtype-specific pharmacological analysis. No prior work had resolved whether alpha(1A), alpha(1B), or alpha(1D) dominates in this context. Understanding this could improve treatments for erectile dysfunction. The study aimed to clarify subtype prevalence through antagonist responses. This work builds on prior pharmacological profiling of adrenergic receptors.

The study aimed to determine the predominant alpha(1)-adrenoceptor subtype in human corpus cavernosum tissue. Researchers focused on characterizing receptor subtype affinities using specific antagonists. The goal was to identify which antagonist produced the strongest inhibition of phenylephrine-induced contractions. This would help distinguish between alpha(1A), alpha(1B), and alpha(1D) subtypes. The motivation came from the need to improve pharmacological management of erectile dysfunction. Prior work suggested alpha(1)-adrenoceptors regulate cavernosal smooth muscle tone. This study sought to confirm subtype dominance through functional assays. The findings could guide the development of more selective adrenergic drugs.

Cavernosal tissue samples were collected from 22 men undergoing gender re-assignment surgery. Tissue strips were placed in organ baths with Krebs' solution to maintain viability. Phenylephrine concentration-response curves were generated to assess baseline contractility. Tissues were then incubated with subtype-specific antagonists at 1 micromolar concentrations. Three antagonists were tested: WB4101 (alpha(1A)), chloroethylclonidine (alpha(1B)), and BMY 7378 (alpha(1D)). The CRCs were repeated after each antagonist incubation. EC(50) values and pK(B) values were calculated to quantify receptor affinity. The method relied on functional pharmacological profiling rather than molecular techniques.

WB4101 produced a parallel rightward shift in the phenylephrine CRC with a pK(B) of 7.49. BMY 7378 also shifted the CRC but with a lower pK(B) of 6.45. Chloroethylclonidine had the weakest effect with a pK(B) of 5.90. These values indicate higher affinity for WB4101 compared to the other antagonists. The alpha(1)-adrenoceptors in cavernosal tissue showed greater sensitivity to alpha(1A) antagonists. This suggests the alpha(1A) subtype is predominant in this tissue. The results support the hypothesis that alpha(1A) receptors are most functionally relevant. The study provides quantitative evidence for subtype-specific affinities.

The study confirms that alpha(1A)-adrenoceptors are the predominant subtype in human corpus cavernosum. This conclusion is based on the observed pK(B) values for the tested antagonists. WB4101 produced the strongest inhibition of phenylephrine-induced contractions. The findings suggest that alpha(1A) receptors have higher affinity for this antagonist. The authors propose that these results may aid in developing more selective adrenergic drugs. No prior work had resolved this subtype dominance in cavernosal tissue. The results align with the hypothesis that alpha(1A) receptors are most functionally relevant. The study provides a pharmacological basis for subtype-specific drug development.